AACI (Association of American Cancer Institutes) shared a post on LinkedIn:
“Clinical trial activation delays cost time, money, and—most critically—patient access to lifesaving treatments.
In the July AACI Commentary, Drs. Diane M. Simeone and Thomas George, co-chairs of the AACI Accelerating Clinical Trials (ACT) Steering Committee, outline why the U.S. risks falling behind global competitors on trial activation speed and highlight how the ACT Steering Committee aims to reduce barriers to timely clinical trial activation through protocol development, start-up and operational efficiencies, regulatory alignment, and stakeholder support.
The ACT Steering Committee is tasked with developing scalable, national solutions, with recommendations to be shared this October at the 2026 AACI/CCAF Annual Meeting in Chicago.”
UF Health Cancer Institute shared this post, adding:
“Thomas George, M.D., FACP, FASCO, our interim director, co-authored this new AACI Commentary describing a vision for the next era of oncology clinical trials in the United States.
Dr. George serves as co-chair of the AACI Accelerating Clinical Trials Steering Committee, which is tasked with developing scalable, national solutions to reducing barriers to timely clinical trial activation.”
Other posts about Association of American Cancer Institutes on OncoDaily.